Protective T cell responses against tumors require the production of Interferon gamma (IFN-γ). However, tumor-infiltrating T cells (TILs) gradually lose their capacity to produce IFN-γ and therefore fail to clear malignant cells. Dissecting the underlying mechanisms that block cytokine production is thus key for improving T cell products.
Introduction
Cytotoxic CD8 + T cells can be very potent in anti-tumoral therapies. In fact, more than 50% of the patients suffering from metastatic melanoma respond to T cell therapy with ex vivo expanded tumor-infiltrating T cells (TILs), of which 10-20% experience complete remission (1, 2) .
A critical feature of CD8 + T cell responses is the release of effector molecules, and the pro-inflammatory cytokine interferon gamma (IFN-γ) is key herein. Deletion of the IFN-γ gene, and loss of the IFN-γ receptor signaling pathway resulted in spontaneous tumor development in mice, and in loss of tumor suppression (3, 4) . A high IFN-γ-mediated gene signature has been associated with better survival for melanoma patients (5). In addition, genetic screens revealed that modulating IFN-γ responses in tumors leads to loss of responsiveness to immunotherapies (6), which is further emphasized by the fact that genetic variations of the interferon signaling pathway in humans correlate with cancer risk and survival (7) .
A major limitation of effective anti-tumor responses by TILs is the loss of effector function, i.e. the failure to produce effector molecules such as . Several signals can drive this loss of cytokine production, such as chronic exposure to antigen and to inhibitory molecules, restriction of glucose, and increase of fatty acid oxidation (11) (12) (13) (14) (15) (16) . However, these events do not fully explain the loss of effector function within the tumor microenvironment.
2, and IFN-γ with a similar sensitivity (Fig 2A, Fig S1A) . Nevertheless, the percentage of IFN-γ producing ARE-Del T cells was significantly higher (Fig 2A) .
To determine how T cells responded to established tumors in vivo, we injected 1x10 6 in vitro activated and expanded WT or ARE Del OT-I T cells into B16-OVA tumor-bearing mice that were injected with 3x10 5 cells subcutaneously 7-10 days earlier. 14 days post T cell transfer, we analysed the phenotype and the effector function of tumor-infiltrating T cells (TILs). The percentage of WT and ARE-Del T cell infiltrates and their expression levels of CD44 and CD62L was equal ( Fig 2B, C) , and the percentage of TILs expressing the degranulation marker CD107a was not different between WT and ARE-Del TILs ( Fig   2D) .
Chronically activated T cells gradually lose their capacity to produce effector molecules (28) . In line with that, the production of TNF-α and IL-2 by WT and ARE-Del TILs was undetectable ( Fig 2D) . Also the production of IFN-γ was limited, with a mere 19±8% of WT TILs producing detectable levels directly ex vivo (Fig 2E) . In sharp contrast, 62±10% ARE-Del T cells produced IFN-γ ( Fig 2E) . The superior IFN-γ production of ARE-Del T cells was also evident from the IFN-γ production per cell, as measured by mean fluorescence intensity levels of the IFN-γ + T cells (Fig 2E) . Of note, the higher IFN-γ production by ARE-Del T cells was independent of the tumor size ( Fig 2F) . Furthermore, whereas the addition of exogenous OVA 257-264 peptide to spleen-derived T cells from tumor-bearing mice resulted in massive cytokine production, TILs were unresponsive to additional antigen (Fig 2G, S1B) . Only bypassing the proximal TCR signaling with PMA/ionomycin resulted in potent IFN-γ production of WT TILs (Fig 2G, S1B) , implying that regulatory factors other than antigen loss caused the block of IFN-γ production in this model. In conclusion, AREs within the Ifng locus promote the loss of IFN-γ production in TILs through post-transcriptional repression.
ARE-Del T cell therapy substantially delays the tumor outgrowth
To determine whether ARE-Del T cells also had a higher therapeutic potential, we followed the tumor outgrowth in B16-OVA tumor-bearing mice that were left untreated, or that received 1x10 6 WT, or ARE-Del OT-I T cells. Mice that did not receive T cell therapy reached the maximal acceptable tumor size of 1000mm 3 within 20 days post tumor injection ( Fig 3A, B) . As previously shown (27), T cell therapy with WT OT-I T cells significantly delayed the tumor outgrowth ( Fig 3A) , and it increased the 50% survival rate from 18 days to 25 days (p=0.0005; Fig 3B) . Remarkably, T cell transfer with ARE-Del T cells substantially extended this therapeutic effect, increasing the 50% survival rate from 25 days to a striking 43 days when compared to T cell transfer with WT T cells (p=0.02; Fig 3A, B) . Altogether, our data demonstrate that the removal of AREs within the Ifng 3'UTR suffices to significantly potentiate the therapeutic effects of T cell therapy.
Increased IFN-γ production by ARE-Del TILs alters the phenotype of macrophages
IFN-γ can exert pleiotropic effects on the immune system and on the inflamed tissue (29, 30) . To identify the mechanisms that ARE-Del T cells use to block the tumor outgrowth, we first analyzed the composition and functionality of lymphoid and myeloid tumor infiltrates. The absolute numbers of live CD45 + cells were equal in tumors from mice treated with WT or ARE-Del T cells ( Fig 4A) . This was also reflected by similar percentages of CD3 + T cells, CD8 + T cells, CD4 + T cells, regulatory T cells, NK cells, and B cells found within the lymphoid infiltrates ( Fig 4B) . Furthermore, the endogenous CD8 + T cell and NK cell infiltrates had a similar potential to produce IFN-γ or to express the degranulation marker CD107a ( Fig S1C) .
To study the myeloid tumor infiltrates, we distinguished three different populations based on their forward scatter/side scatter profile and on the expression of CD11b, Ly6G/C and F4/80 (31). The percentage of tumor-infiltrating CD11b hi Ly6G/C hi neutrophils was equal in tumors treated with WT and ARE-Del T cells ( Fig 4C) , and their activation status did not change as judged from the expression levels of CD63 and ICAM-1 (CD54) ( Fig   S1D) . Likewise, migrating CD11b hi F4/80 int monocytes that represent the major source of macrophages in inflamed tissues (31) did not change ( Fig 4C, D) . Interestingly, the percentage of fully differentiated CD11b hi F4/80 hi macrophages consistently increased from 7±3% in mice treated with WT T cells to 12±4% in mice that received ARE-Del T cells (p=0.0057; Fig 4C, D) . CD11b hi F4/80 hi macrophages expressed higher MHC-I and MHC-II levels than the CD11b hi F4/80 int monocytic fraction ( Fig 4E) . Treatment with ARE-Del T cells further enhanced the levels of MHC-II ( Fig 4E) , and reduced the expression levels of the mannose receptor CD206 ( Fig 4F) , a marker that is associated with the anti-inflammatory phenotype of macrophages (32). These findings thus indicate that the continuous IFN-γ production in tumors by ARE-Del T cells augments the numbers of tumor-associated macrophages with a pro-inflammatory phenotype.
Continuous IFN-γ production by ARE-Del T cells directly affects the tumor outgrowth
IFN-γ can also directly act on tumor cells (30). Indeed, treating B16-OVA melanoma cells with recombinant IFN-γ (rIFN-γ) induced the expression of PD-L1, MHC-I and MHC-II, which was completely lost when the IFN-γ receptor 1 was deleted by CRISPR/Cas9 (IFN-γR -/-) ( Fig S1E, F) . Similarly, high expression levels of PD-L1, MHC-I and MHC-II were found on tumor cells ex vivo after treatment with WT T cells, and these markers were further enhanced upon ARE-Del T cell therapy ( Fig 5A) . We next investigated whether higher levels of IFN-γ could also directly affect the proliferation of tumor cells. B16-OVA cells cultured in vitro with rIFN-γ lost their capacity to expand ( Fig 5B) , which was at least in part due to a block in proliferation as determined with the cell trace dye CFSE ( Fig 5C) . As expected, IFN-γR -/-B16-OVA cells were refractory to rIFN-γ ( Fig 5B, C) . Importantly, we confirmed this block of proliferation in vivo. The incorporation of thymidine analog bromodeoxyuridine (BrdU) revealed that the absolute number of tumor cells in S phase (BrdU + ) was significantly lower in B16-OVA tumors isolated from mice treated with ARE-Del T cells than from mice treated with WT T cells ( Fig 5D, left panel) . This decline in tumor cell proliferation directly correlated with the superior IFN-γ production by ARE-Del TILs (Fig 5D, right panel).
We next determined the effect of IFN-γ in vivo on B16-OVA IFN-γR -/and Cas9 control tumors in mice treated with WT or ARE-Del T cells. Again, the percentage of OT-I T cell 1 0 infiltrates was equal, and ARE-Del T cells maintained their superior production of IFN-γ, whether the tumors expressed IFN-γR or not ( Fig 5E, F) . However, the therapeutic advantage of ARE-Del T cells over WT T cells was completely lost on IFN-γR -/tumors ( Fig 5G) . In conclusion, relieving IFN-γ from post-transcriptional regulation boosts the therapeutic potential of T cell therapy predominately through direct effects of IFN-γ on the tumor cells.
IFN-γ production by ARE-Del T cells correlates with increased mRNA stability
Our data thus far demonstrate that AREs are instrumental in the loss of cytokine production in TILs. This critical role of post-transcriptional regulation is further emphasized by the discrepancy between Ifng mRNA levels and IFN-γ protein levels.
Despite the loss of IFN-γ production, we found that WT TILs maintained higher levels of Ifng mRNA when compared to spleen-derived OT-I T cells ( Fig 6A) . We observed a similar discrepancy in mRNA levels and protein expression in human TILs. Melanomaspecific TILs completely fail to produce IFN-γ protein upon activation (9,33), yet they express higher IFNG mRNA levels when compared to their peripheral blood-derived counterparts (9). Of note, ARE-Del TILs expressed yet another 2-fold more Ifng mRNA than WT TILs ( Fig 6A) .
To dissect the mechanisms that drive the superior IFN-γ production in ARE-Del T cells, we set up an in vitro co-culture system with tumor cells. When antigen-experienced T cells were exposed to B16-OVA tumor cells for 1 day, both WT and ARE-Del OT-I T 1 cells potently produced IFN-γ ( Fig 6B) . However, re-exposure to freshly seeded B16-OVA cells for a second time showed a substantial reduction of the IFN-γ production of WT T cells (from 75±13% to 51±6%), and this response was almost completely lost after a third exposure to B16-OVA cells (9±6%; Fig 6B) . In contrast, ARE-Del T cells maintained their reactivity for an extended period, and 57±15% of the T cells retained their IFN-γ production at day 3 ( Fig 6B) . Intriguingly, irrespective of the loss of cytokine production in WT T cells, the Ifng mRNA levels of WT and ARE-DEL T cells were indistinguishable at day 1 and 2 of co-culture with B16-OVA cells ( Fig 6C) . At day 3, however, ARE-Del T cells maintained significantly higher levels of Ifng mRNA compared to WT T cells ( Fig 6C) . These findings were confirmed with a different tumor cell line, the murine colon adenocarcinoma-derived MC38-OVA cell line. Also upon 3 days of co-culture with MC38-OVA cells, ARE-Del T cells maintained significantly higher levels of IFN-γ production compared to WT T cells ( Fig 6D, Fig S2A) . Again, differences of Ifng mRNA levels between WT and ARE-Del T cells were only observed at day 3, and not upon 1 day of co-culture ( Fig 6E) .
We next determined whether the discrepancy of Ifng mRNA levels between WT and ARE-Del T cells was due to a different capacity to stabilize the Ifng mRNA. Resting WT T cells have a t 1/2 = ~30 min prior to exposure to tumor cells, as determined by blocking de novo transcription with Actinomycin D (Fig 6F; (22) ). When T cells were cultured with B16-OVA or with MC38-OVA tumor cells for 1 day, they substantially increased the stability of Ifng mRNA to t 1/2 > 2h ( Fig 6F) . However, this stability was lost after 3 days of co-culture (t 1/2 = ~1h; Fig 6F) . In sharp contrast, ARE-Del T cells maintained stable Ifng mRNA throughout the entire co-culture (t 1/2 > 2h; Fig 6F) . This disparity of Ifng mRNA turn-over rates was also found in FACS-sorted TILs from B16-OVA tumorbearing mice that displayed a t 1/2 = ~30 min for WT TILs as opposed to t 1/2 > 1h for ARE-Del TILs ( Fig 6G) . Thus, stabilized mRNA and consequentially elevated Ifng mRNA levels potentially promote the superior and prolonged cytokine production by ARE-Del TILs within the tumor environment.
CD28 costimulation but not PD-1 blockade restores IFN-γ production through mRNA stabilization
We next sought to identify signals that support the stabilization of Ifng mRNA in T cells.
Programmed death 1 (PD-1) and Lymphocyte-activation gene 3 (Lag-3) are two exhaustion markers that are highly expressed on tumor-infiltrating T cells ( Fig 7A, Fig   S2B, C) . Blocking PD-1 can effectively reinvigorate T cell responses against tumors (34, 35) . Indeed, co-culturing T cells for 3 days with B16-OVA tumors in combination with αPD-1 blocking antibody significantly increased the production of IFN-γ of WT T cells (from 9±5% to 24±13%; p=0.03), and of ARE-Del T cells (from 66±7% to 79±8%; p=0.04. Fig 7B; S2D) .
Recent studies showed that PD-1 blocks T cell function by interfering with CD28 signaling (36, 37) . In line with that, CD80/CD86 blockade annihilated the increased IFN-γ production of PD-1 blockade, and reduced the levels of IFN-γ back to 8±4% WT and 66±13% ARE-Del T cells ( Fig 7B; S2D) . Interestingly, providing CD28 costimulation to ARE-Del T cells that were cocultured with tumor cells did not increase the IFN-γ production when compared to untreated T cells (Fig 7B, bottom panel; p=0.1) . In sharp contrast, CD28 costimulation significantly restored the responsiveness of WT T cells to levels that were similiar to PD-1 blockade (from 9±5% to 20±11%; p=0.04; Fig 7B; S2D). Combining PD-1 blockade with CD28 costimulation even further augmented the production of IFN-γ by WT T cells when compared to single treatments (34±15%;
p=0.03 compared to αPD-1; p=0.006 compared to αCD28; Fig 7B; S2C ).
Because both CD28 stimulation and PD-1 blockade effectively increased the IFN-γ production in WT T cells, but only PD-1 blockade acted on ARE-Del T cells, it suggested to us that these two pathways may employ different mechanisms. We therefore determined the effect of PD-1 blockade and/or CD28 costimulation on the stability of Ifng mRNA. As expected, irrespective of the antibody treatment, the Ifng mRNA in ARE-Del T cells was always stabilized ( Fig S2E) . However, despite significant increases in the IFN-γ protein production, PD-1 blockade in WT T cells did not increase the Ifng mRNA levels ( Fig S2F) , or its stability ( Fig 7C) . mRNA levels and stability were identical between PD-1 blockade alone or in combination with αCD80/86 ( Fig 7C, S2F ). In sharp contrast, CD28 costimulation effectively stabilized Ifng mRNA in WT T ( Fig 7C) . PD-1 blockade could further potentiate the Ifng mRNA stabilization when combined with CD28 costimulation, which was also concomitant with increased Ifng mRNA levels ( Fig   7C, S2F) . Combined, whereas CD28 signaling and PD-1 blockade primarily govern IFNγ production through different pathways, they collaborate in restoring the production of IFN-γ in tumor-exposed T cells.
Altogether, our study reveals that post-transcriptional regulation blocks the production of IFN-γ in TILs, and that loss of this regulatory mechanism could greatly improve the therapeutic effect of T cell therapy.
Discussion
The production of IFN-γ by TILs is critical for effective anti-tumoral responses. Chronic antigen exposure and immunosuppressive signals within the tumor environment, however, impede the effector function of TILs. Here, we show that the loss of IFN-γ production is linked to rapid Ifng mRNA decay that is mediated by AREs located within its 3'UTR.
Despite the epigenetic changes that arise early during T cell activation (38-40), tumorspecific TILs maintain higher levels of Ifng mRNA. As human melanoma-specific TILs alike, TILs isolated from B16-OVA tumors expressed higher levels of Ifng mRNA than blood-or spleen-derived T cells of the same antigen specificity ((9); Fig 6) . Yet, TILs fail to translate the mRNA into protein (9,33). Even though nutritional and metabolic restrictions within the tumor environment can block protein production (14-16), we show here that the mere removal of ARE sequences from the Ifng 3'UTR is sufficient to bypass this inhibitory state. Thus, mRNA stabilization contributes to ensure effective IFN-γ production by TILs.
Which signals interfere with the stability of Ifng mRNA in TILs is yet to be determined.
We previously showed that PKC signaling is critical for the stabilization of Ifng mRNA in activated T cells (21). CD28 costimulation, which can enhance cytokine mRNA stability (41), also amplifies PKCθ signaling in T cells (42, 43) . In line with that, CD28 costimulatory signals in tumor-exposed T cells effectively stabilized Ifng mRNA and restored IFN-γ protein production.
The recovery of protein production upon PD-1 blockade was similar to that of CD28 costimulation. However, in line with recent studies that found no changes in Ifng mRNA levels and/or epigenetic signature upon PD-1 blockade (38), this treatment also failed to stabilize Ifng mRNA in dysfunctional T cells (Fig 7) . These findings were unexpected because PD-1 signaling recruits SHP-1/2 and dephosphorylates Zap70, which in turn inactivates PKC signaling (44). Interestingly, PD-1 signaling recruits SHP2 also to CD28
and thus blocks T cell function by inactivating CD28 signaling (36). The efficacy of anti PD-1 therapy may therefore depend on the levels of actual CD28 signaling (37). That CD28 signaling stabilizes Ifng mRNA while PD-1 blockade fails to do so could therefore result from different signal strengths from these two antibody treatments. Alternatively, PD-1 blockade may also act on signaling pathways other than those involved in mRNA stabilization, which may or may not become engaged by CD28 costimulation. Because mRNA levels and stability do not change upon PD-1 blockade, but the IFN-γ protein production resembles that of CD28 costimulation, it is tempting to speculate that the observed IFN-γ protein production upon PD-1 blockade is mediated through increased translation efficiency. How the translational block is regulated in TILs is yet to be determined. We recently showed that the RNA-binding protein ZFP36L2 blocks translation of Ifng mRNA in memory T cells by interacting with the ARE region (Salerno et al., Nature Immunology, in press). It is therefore conceivable that similar mechanisms are at play in TILs.
In conclusion, post-transcriptional regulatory mechanisms impede the production of IFNγ by TILs. Removing AREs in only one Ifng allele in the transferred T cells, as we did in this study, is already sufficient to restore the production of IFN-γ to levels that effectively delay the tumor outgrowth. Interfering with the turn-over rate of Ifng mRNA, e.g. by genetically altering the cis-elements on the mRNA to interfere with post-transcriptional regulation could thus significantly potentiate the efficacy of T cell therapy against tumors. Cells were cultured in IMDM (GIBCO-BRL) supplemented with 8% FCS, 15μM 2mercaptoethanol, 2mM L-Glutamine, 20 U/mL penicillin G sodium, and 20μg/mL streptomycin sulfate.
Material and Methods

Mice
In vitro T cell activation and Listeria monocytogenes-OVA infection
FACS-sorted naive CD8 + CD44 lo CD62L hi T cells from WT or ARE-Del OT-I splenocytes were co-cultured for 1 or 3 days with bone marrow-derived DCs loaded with indicated amounts of OVA 257-264 peptide as previously described (21) 
B16 melanoma tumor model
For in vivo studies, mice were injected subcutaneously with 3×10 5 B16-OVA cells (27) For in vitro studies, WT and ARE-Del OT-I T cells were activated for 20h with MEC.B7.SigOVA cells, cultured for 4 days with rIL-2 in the absence of antigen, and then reactivated by co-culture with pre-seeded B16-OVA or MC38-OVA cells for 1 to 3 days.
B16-OVA or MC38-OVA cells were refreshed daily at a 6:1 effector:target ratio. When indicated, T cells were daily treated with 10μg/ml of the following purified antibodies:
anti-mouse CD28 (PV-1; Bioceros), anti-mouse CD279 (PD-1; 29F.1A12), anti-mouse CD80 (16-10A1), and anti-mouse CD86 (GL-1; all eBioscience). 1
Flow cytometry
T cells were washed with FACS buffer (phosphate-buffered saline [PBS], containing 1%
FCS and 2mM EDTA) and labeled for 20 min at 4°C with the following monoclonal antibodies (all from eBioscience): anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD3 (17A2), anti-CD8 (53-6.7), anti-CD4 (GK1.5), anti-FoxP3 (FJK-16s), anti-CD44 (IM7), 3  5  .  T  o  p  a  l  i  a  n  S  L  ,  H  o  d  i  F  S  ,  B  r  a  h  m  e  r  J  R  ,  G  e  t  t  i  n  g  e  r  S  N  ,  S  m  i  t  h  D  C  ,  M  c  D  e  r  m  o  t  t  D  F   ,  e  t  a  l  .   S  a  f  e  t  y  ,   a  c  t  i  v  i  t  y  ,  a  n  d  i  m  m  u  n  e  c  o  r  r  e  l  a  t  e  s  o  f  a  n  t  i  -P  D  -1  a  n  t  i  b  o  d  y  i  n  c  a  n  c  e  r  .  T  h  e  N  e  w  E  n  g  l  a  n  d   j  o  u  r  n  a  l  o  f  m  e  d  i  c  i  n  e   2  0  1  2   ;  3  6  6  :  2  4  4  3  -5  4   3  6  .  H  u  i  E  ,  C  h  e  u  n  g  J  ,  Z  h  u  J  ,  S  u  X  ,  T  a  y  l  o  r  M  J  ,  W  a  l  l  w  e  b  e  r  H  A   ,  e  t  a  l  .   T  c  e  l  l  c  o  s  t  i  m  u  l  a  t  o  r 
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